Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis

BACKGROUND: Erythropoiesis‐stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Balleari, Enrico, Filiberti, Rosa Angela, Salvetti, Chiara, Allione, Bernardino, Angelucci, Emanuele, Bruzzone, Marco, Calzamiglia, Tullio, Cavaliere, Marina, Cavalleri, Maurizio, Cilloni, Daniela, Clavio, Marino, Crisà, Elena, Da Col, Anna, Danise, Paolo, Pilo, Federica, Ferrero, Dario, Finelli, Carlo, Gioia, Daniela, Lemoli, Roberto Massimo, Masiera, Elisa, Messa, Emanuela, Miglino, Maurizio, Musto, Pellegrino, Natalie Oliva, Esther, Poloni, Antonella, Salvi, Flavia, Sanna, Alessandro, Scudeletti, Marco, Tassara, Rodolfo, Santini, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912022/
https://www.ncbi.nlm.nih.gov/pubmed/31657156
http://dx.doi.org/10.1002/cam4.2638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912022/
https://www.ncbi.nlm.nih.gov/pubmed/31657156
http://dx.doi.org/10.1002/cam4.2638

Ejemplares similares